NCT06868264进行中（未招募）3 期
Phase 3, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvir-Ruzasvir Fixed-dose Combination (BEM/RZR FDC) Versus Sofosbuvir-Velpatasvir Fixed-dose Combination (SOF/VEL FDC) in Subjects With Chronic Hepatitis C Virus (HCV) Infection
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 880
- 试验地点
- 1
- 主要终点
- Proportion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at study week 24.
研究概览
简要总结
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Use of adequate contraception for females of childbearing potential
- •Must be direct-acting antiviral (DAA)-treatment-naïve (never exposed to an approved or experimental DAA for HCV)
- •Documented medical history compatible with chronic HCV
- •Either no liver cirrhosis or with compensated liver cirrhosis
- •If HIV-1-positive, must meet the following 2 criteria:
- •Antiretroviral (ARV) regimen for >8 weeks prior to screening visit, with CD4 T-cell count >200 cells/mm3 and plasma HIV-1 RNA <LLOQ
- •Suitable ARV treatment and not taking any contraindicated medications
排除标准
- •Pregnant or breastfeeding
- •Co-infected with hepatitis B virus
- •Abuse of alcohol and/or illicit drug use that could interfere with adherence to study requirements as judged by the investigator
- •Requirement of any prohibited medications
- •Use of other investigational drugs within 30 days of dosing
- •History or signs of decompensated liver disease (decompensated cirrhosis)
- •History of hepatocellular carcinoma (HCC)
- •Any other clinically significant medical condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results
研究组 & 干预措施
Bemnifosbuvir-Ruzasvir (BEM/RZR)
Experimental
干预措施: Bemnifosbuvir-Ruzasvir (BEM/RZR) (Drug)
Sofosbuvir-Velpatasvir (SOF/VEL)
Active Comparator
干预措施: Sofosbuvir-Velpatasvir (SOF/VEL) (Drug)
结局指标
主要结局
Proportion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at study week 24.
时间窗: Day 1 through Week 24
次要结局
- Proportion of subjects achieving HCV RNA < LLOQ 12 weeks after the last dose of study drugs.(Day 1 through 12 weeks after the end of treatment)
- Proportion of subjects experiencing virologic failure.(Day 1 through Week 24)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
PEG-rhG-CSF in Patients With Breast Cancer Receiving ChemotherapyBreast CancerNCT02805153CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.215
进行中（未招募）
2 期
A Study of Barzolvolimab in Patients With Prurigo NodularisPrurigo NodularisNCT06366750Celldex Therapeutics140
已完成
3 期
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) MelanomaCancerNCT01227889GlaxoSmithKline251
已完成
1 期
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple MyelomaRefractory Multiple MyelomaRelapsed Multiple MyelomaMultiple MyelomaNCT00153933Dana-Farber Cancer Institute58
已完成
2 期
An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple MyelomaMultiple MyelomaNCT00431769Janssen-Cilag International NV130